ZA201704463B - Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same - Google Patents

Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Info

Publication number
ZA201704463B
ZA201704463B ZA2017/04463A ZA201704463A ZA201704463B ZA 201704463 B ZA201704463 B ZA 201704463B ZA 2017/04463 A ZA2017/04463 A ZA 2017/04463A ZA 201704463 A ZA201704463 A ZA 201704463A ZA 201704463 B ZA201704463 B ZA 201704463B
Authority
ZA
South Africa
Prior art keywords
hepe
compositions
treating
methods
same
Prior art date
Application number
ZA2017/04463A
Other languages
English (en)
Inventor
Climax John
Duffy Kevin
Rowe Jonathan
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of ZA201704463B publication Critical patent/ZA201704463B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/04463A 2014-12-02 2017-06-30 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same ZA201704463B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (1)

Publication Number Publication Date
ZA201704463B true ZA201704463B (en) 2018-11-28

Family

ID=56092410

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2017/04463A ZA201704463B (en) 2014-12-02 2017-06-30 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
ZA2018/04380A ZA201804380B (en) 2014-12-02 2018-06-29 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2018/04380A ZA201804380B (en) 2014-12-02 2018-06-29 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Country Status (17)

Country Link
US (1) US10363235B2 (enExample)
EP (2) EP3226873B1 (enExample)
JP (2) JP6986445B2 (enExample)
KR (1) KR20170102879A (enExample)
CN (2) CN107206008A (enExample)
AU (2) AU2015358512B2 (enExample)
BR (1) BR112017011685A2 (enExample)
CA (1) CA2968980A1 (enExample)
ES (1) ES2900593T3 (enExample)
IL (2) IL252431B (enExample)
MA (1) MA41120A (enExample)
MX (2) MX382116B (enExample)
PH (1) PH12017501022B1 (enExample)
RU (2) RU2721555C2 (enExample)
SG (2) SG10202010594WA (enExample)
WO (1) WO2016090030A1 (enExample)
ZA (2) ZA201704463B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
WO2008021192A2 (en) * 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
BR112014006220A2 (pt) * 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CA2859573A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP4205546A1 (en) 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
IL252431A0 (en) 2017-07-31
IL287983A (en) 2022-01-01
KR20170102879A (ko) 2017-09-12
PH12017501022B1 (en) 2022-02-16
EP3226873A1 (en) 2017-10-11
AU2015358512A1 (en) 2017-07-20
EP3988101A1 (en) 2022-04-27
JP2022031813A (ja) 2022-02-22
MA41120A (fr) 2017-10-10
PH12017501022A1 (en) 2017-11-27
MX2021005080A (es) 2021-06-15
RU2017122758A3 (enExample) 2019-06-13
BR112017011685A2 (pt) 2018-01-02
US10363235B2 (en) 2019-07-30
AU2015358512B2 (en) 2021-02-18
EP3226873B1 (en) 2021-10-27
RU2020115523A (ru) 2021-01-27
CN107206008A (zh) 2017-09-26
SG11201704495VA (en) 2017-06-29
US20160184252A1 (en) 2016-06-30
RU2017122758A (ru) 2019-01-09
ES2900593T3 (es) 2022-03-17
MX382116B (es) 2025-03-13
EP3226873A4 (en) 2018-08-08
CA2968980A1 (en) 2016-06-09
WO2016090030A1 (en) 2016-06-09
CN112245419A (zh) 2021-01-22
HK1245101A1 (zh) 2018-08-24
AU2021203189A1 (en) 2021-06-10
ZA201804380B (en) 2021-03-31
JP6986445B2 (ja) 2021-12-22
IL252431B (en) 2021-12-01
SG10202010594WA (en) 2020-12-30
RU2721555C2 (ru) 2020-05-20
JP2017536380A (ja) 2017-12-07
MX2017007000A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
IL257307B (en) Transgenic crispr–cas9 preparations and methods of use
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA201701909B (en) Trichoderma compositions and methods of use
PL3349743T3 (pl) Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12
LT3189074T (lt) Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
ZA201804380B (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
ZA201900044B (en) Tuberculosis compositions and methods of treating or preventing tuberculosis
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
ZA201607878B (en) Compositions and methods of treating cardiac fibrosis with ifetroban
SG11201803284YA (en) Novel method of use and compositions
GB201511799D0 (en) Composition and methods of treatment
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL273850A (en) Preparations and methods for the treatment of leprosy
GB201621737D0 (en) Compositions and methods of treatment
IL261794A (en) Preparations and methods for using them
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
GB201605127D0 (en) Composition and methods of treatment
EP3194446A4 (en) Compositions and methods for treating fibrosis
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
AU2015903210A0 (en) Compositions and methods of treatment
GB201521083D0 (en) Compositions for treatment and methods thereof
SG11201704282UA (en) Compositions and methods for the treatment of multiple sclerosis
GB201409262D0 (en) Hair treatment compositions and methods